These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 9244718)
1. [Comparison of anti-arrhythmic therapy guided by the transesophageal electropharmacologic test and emperic therapy in the prophylaxis of atrial fibrillation recurrence]. Fera MS; Carunchio A; Burattini M; Mazza A; Coletta C; Galati A; Ceci V G Ital Cardiol; 1997 Feb; 27(2):152-63. PubMed ID: 9244718 [TBL] [Abstract][Full Text] [Related]
2. [A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation]. Carunchio A; Fera MS; Mazza A; Burattini M; Greco G; Galati A; Ceci V G Ital Cardiol; 1995 Jan; 25(1):51-68. PubMed ID: 7642012 [TBL] [Abstract][Full Text] [Related]
3. [The role of an electropharmacological transesophageal test in the prevention of paroxysmal atrial fibrillation. Experience with flecainide]. De Sisti A; Matteucci C; Patrissi T; Accogli S; Di Lorenzo M; Sasdelli M; Ciolli A; Lo Sardo G; Palamara A G Ital Cardiol; 1998 Dec; 28(12):1391-9. PubMed ID: 9887393 [TBL] [Abstract][Full Text] [Related]
4. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. Circulation; 1995 Nov; 92(9):2550-7. PubMed ID: 7586356 [TBL] [Abstract][Full Text] [Related]
5. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. Pappone C; Augello G; Sala S; Gugliotta F; Vicedomini G; Gulletta S; Paglino G; Mazzone P; Sora N; Greiss I; Santagostino A; LiVolsi L; Pappone N; Radinovic A; Manguso F; Santinelli V J Am Coll Cardiol; 2006 Dec; 48(11):2340-7. PubMed ID: 17161267 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of sequential antiarrhythmic treatment in sinus rhythm maintenance after successful electrocardioversion in patients with chronic non-valvular atrial fibrillation. Kosior D; Opolski G; Torbicki A Med Sci Monit; 2001; 7(1):68-73. PubMed ID: 11208496 [TBL] [Abstract][Full Text] [Related]
7. [Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study]. Bellandi F; Dabizzi RP; Niccoli L; Cantini F; Palchetti R G Ital Cardiol; 1996 Apr; 26(4):379-90. PubMed ID: 8707022 [TBL] [Abstract][Full Text] [Related]
8. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. Roy D; Talajic M; Dorian P; Connolly S; Eisenberg MJ; Green M; Kus T; Lambert J; Dubuc M; Gagné P; Nattel S; Thibault B N Engl J Med; 2000 Mar; 342(13):913-20. PubMed ID: 10738049 [TBL] [Abstract][Full Text] [Related]
9. An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. Brignole M; Menozzi C; Gasparini M; Bongiorni MG; Botto GL; Ometto R; Alboni P; Bruna C; Vincenti A; Verlato R; Eur Heart J; 2002 Jun; 23(11):892-900. PubMed ID: 12042011 [TBL] [Abstract][Full Text] [Related]
10. [The effects of the ablation of atrial flutter in patients with and without a clinical history of paroxysmal atrial fibrillation]. De Sisti A; Leclercq JF; Fiorello P; Palamara A; Attuel P G Ital Cardiol; 1998 Nov; 28(11):1253-60. PubMed ID: 9866803 [TBL] [Abstract][Full Text] [Related]
11. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial. Gulizia M; Mangiameli S; Orazi S; Chiarandà G; Piccione G; Di Giovanni N; Colletti A; Pensabene O; Lisi F; Vasquez L; Grammatico A; Boriani G; Am Heart J; 2008 Jan; 155(1):100-7, 107.e1. PubMed ID: 18082498 [TBL] [Abstract][Full Text] [Related]
12. [Propafenone and flecainide in the therapy of ventricular arrhythmias]. Paperini L; Davini A; Lattanzi F; Topi A; Reisenhofer B; Squarcini G; Paci A; Topi PL Minerva Cardioangiol; 1995 Oct; 43(10):449-57. PubMed ID: 8819814 [TBL] [Abstract][Full Text] [Related]
13. Partial reversal by exercise of protective effect in atrial fibrillation inducibility in patients with an accessory atrioventricular connection: comparison between flecainide and propafenone. Auricchio A; Auricchio U; Chiariello L G Ital Cardiol; 1994 Feb; 24(2):131-6. PubMed ID: 8013765 [TBL] [Abstract][Full Text] [Related]
14. [Comparative study of cibenzoline and flecainide by oral route for preventing recurrence of paroxysmal atrial tachyarrhythmias]. Maison-Blanche P; Brembilla-Perrot B; Fauchier JP; Babuty D; Garnier LF; Rouesnel P; Breuillac JC; Funck F; Scheck F; Peraudeau P; Medvedowsky JL Ann Cardiol Angeiol (Paris); 1997 Feb; 46(2):109-16. PubMed ID: 9137677 [TBL] [Abstract][Full Text] [Related]
15. The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation. Frick M; Darpö B; Ostergren J; Rosenqvist M Eur Heart J; 2000 Jul; 21(14):1177-85. PubMed ID: 10924301 [TBL] [Abstract][Full Text] [Related]
17. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. Mason JW N Engl J Med; 1993 Aug; 329(7):452-8. PubMed ID: 8332150 [TBL] [Abstract][Full Text] [Related]